Innovus Pharmaceuticals Inc. (fka INNV)

[healthywelth]

If, If , … ? But, We concluded that "the risk-reward of the stock at current levels merits the attention of long investors... and further, we believe that Janssen considers imetelstat to be a core part of its pipeline and view the continuation of the Geron agreement to be likely." Based on yesterday's comments from JNJ Chairman and CEO Alex Gorsky, we reiterate our view that Geron remains a priority for Janssen and JNJ.

https://www.equities.com/news/geron-s-imetelstat-reaffirmed-as-a-priority-for-johnson-johnson




•Median Overall Survival Keeps Growing In Unprecedented 25+ Months In The Myelofibrosis iMbark Trial.

•iMerge Part 1 Expansion Phase is now beyond critical 8 Week point for transfusion independence.

•Shorts run out of supply for stocks to cover as 2015 ATM program is now complete; shares available will now dry up very quickly.


Today's Q4 announcement confirms the strong collaboration between Geron (GERN) and Johnson and Johnson (JNJ) remains strong and is moving forward. Median Overall Survival has not yet been reached in the Myelofibrosis "MF" trial iMbark and iMerge has now passed the 8 week critical point. All systems go, as they say, for the collaboration and for Geron shareholders.


https://seekingalpha.com/instablog/3163201-medtechbio/5157556-systems-go-geron-jnj-imerge-imbark-trials-mf-mds